newsfilter
← Latest News
Business Wire·

Infinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer under Nasdaq Listing Rule 5635(c)(4)

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced